Skip to main content
Top

Cancer Chemotherapy and Pharmacology

Issue 6/2023

Content (8 Articles)

Solid Tumor Review Article

Long non-coding RNAs: controversial roles in drug resistance of solid tumors mediated by autophagy

Mohamed J. Saadh, Muhammad Ali Abdulllah Almoyad, Meryelem Tania Churampi Arellano, Renato R. Maaliw III, Roxana Yolanda Castillo-Acobo, Sarah Salah Jalal, Kumaraswamy Gandla, Mohammed Obaid, Asmaa Jamal Abdulwahed, Azher A. Ibrahem, Ioan Sârbu, Ashima Juyal, Natrayan Lakshmaiya, Reza Akhavan-Sigari

Neutropenia Original Article

A polymorphism in ABCA2 is associated with neutropenia induced by capecitabine in Japanese patients with colorectal cancer

Yukitaka Shibata, Natsumi Matsumoto, Remi Murase, Yutaro Kubota, Hiroo Ishida, Ken Shimada, Ken-ichi Fujita

Anemia Original Article

Cytidine deaminase enzyme activity is a predictive biomarker in gemcitabine-treated cancer patients

Alireza Abbaspour, Mehdi Dehghani, Mahtab Setayesh, Marjan Tavakkoli, Hossein Ali Rostamipour, Marziyeh Ghorbani, Mani Ramzi, Shapour Omidvari, Fatemeh Moosavi, Omidreza Firuzi

Salbutamol Original Article

The Beta2-adrenergic agonist salbutamol synergizes with paclitaxel on cell proliferation and tumor growth in triple negative breast cancer models

Martina Jabloñski, María Sol Rodríguez, Ezequiel Mariano Rivero, Carlos David Bruque, Silvia Vanzulli, Ariana Bruzzone, Cecilia Pérez Piñero, Isabel Alicia Lüthy

Cytostatic Therapy Original Article

Clinical outcomes and response to chemotherapy in a cohort of pancreatic cancer patients with germline variants of unknown significance (VUS) in BRCA1 and BRCA2 genes

Anna Maria Militello, Giulia Orsi, Alessandro Cavaliere, Monica Niger, Antonio Avallone, Lisa Salvatore, Giampaolo Tortora, Ilario Giovanni Rapposelli, Guido Giordano, Silvia Noventa, Elisa Giommoni, Silvia Bozzarelli, Marina Macchini, Umberto Peretti, Letizia Procaccio, Alberto Puccini, Stefano Cascinu, Cristina Montagna, Michele Milella, Michele Reni

Webinar | 19-02-2024 | 17:30 (CET)

Keynote webinar | Spotlight on antibody–drug conjugates in cancer

Antibody–drug conjugates (ADCs) are novel agents that have shown promise across multiple tumor types. Explore the current landscape of ADCs in breast and lung cancer with our experts, and gain insights into the mechanism of action, key clinical trials data, existing challenges, and future directions.

Dr. Véronique Diéras
Prof. Fabrice Barlesi
Developed by: Springer Medicine